New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
10:05 EDTAKR, MCD, MPEL, SYT, RHHBY, TSM, DST, AET, ATHNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Acadia Realty Trust (AKR) upgraded to Outperform from Market Perform at BMO Capital... McDonald's (MCD) upgraded to Buy from Neutral at Janney Capital... Melco Crown (MPEL) upgraded to Overweight from Neutral at JPMorgan... Syngenta (SYT) upgraded to Neutral from Underweight at JPMorgan...Roche (RHHBY) upgraded to Overweight from Equal Weight at Morgan Stanley... TSMC (TSM) upgraded to Outperform from Neutral at Credit Suisse... DST Systems (DST) upgraded to Buy from Neutral at Sterne Agee... Aetna (AET) upgraded to Overweight from Neutral at JPMorgan... athenahealth (ATHN) upgraded to Outperform from Market Perform at Leerink.
News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Check below for free stories on AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 8, 2014
09:37 EDTMCDActive equity options trading on open
Subscribe for More Information
09:15 EDTMCDOn The Fly: Pre-market Movers
HIGHER: NVIDIA (NVDA), up 4.2%, upgraded at Needham following its better than expected Q2 results... Arista Networks (ANET), up 8%, upgraded at Citigroup following better than expected Q2 results, announcing an expanded strategic relationship with VMware (VMW)... Tekmira Pharmaceuticals (TKMR), up 17.5% after announcing that the FDA verbally confirmed they have modified the full clinical hold placed on its TKM-Ebola treatment to a partial clinical hold... Gap (GPS), up 4.7% after July same-store sales rose 2%, company issues Q2 EPS outlook above the consensus estimate... lululemon (LULU), up 2.4% after founder agrees to sell half his stake to Advent for $845M. UP AFTER EARNINGS: SolarCity (SCTY), up 1%... Assured Guaranty (AGO), up 9%... MercadoLibre (MELI), up 13.6%. LOWER: Zynga (ZNGA), down 6% after lowering fiscal 2014 guidance... McDonald's (MCD), down 0.4% after Chinese supplier issue contributes to July comparable sales drop of 2.5%.
08:34 EDTMCDMcDonald's warns 2014 comparable sales forecast at risk due to China issue
Subscribe for More Information
08:02 EDTMCDMcDonald's: AMPEA's sales reflect negative impact of food quality issues
Subscribe for More Information
07:58 EDTMCDMcDonald's rejports July global comparable sales down 2.5%
Subscribe for More Information
06:11 EDTMCDOSI withdraws products made in Shanghai in response to food scandal
After dealing with a food scandal, OSI China, parent company of Shanghai Husi Food, announced the withdrawal of products produced in Shanghai. The company said, "Husi is the subject of company and government investigations and it is proceeding smoothly. While there have been no reported illnesses linked to any Shanghai Husi products, recovering this production is an important step in facilitating the investigations and rebuilding the respect and trust of our customers, the government and the people of China. With assistances and guidance provided by Shanghai FDA, we have started the recovery process of products in question in a comprehensive and orderly." Worldwide brands such Yum! Brands (YUM) McDonald's (MCD) and Starbucks (SBUX) were affected by the scandal in China. Reference Link
August 7, 2014
14:06 EDTAETReinsurance Group names Tim Matson as Chief Investment Officer
Subscribe for More Information
14:05 EDTRHHBYPTC Therapeutics reports publication of preclinical study results in SMA models
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
13:23 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
12:29 EDTAETHealth insurers fall after two downgrades from Goldman
Shares of a number of health insurers are falling after Goldman Sachs downgraded its rating on one stock in the sector and removed another from its Conviction List. WHAT'S NEW: Goldman analyst Matthew Borsch downgraded his rating on Aetna (AET) to Neutral from Buy and removed UnitedHealth (UNH) from the firm's Conviction List, as he believes that other stocks in the healthcare sector are more attractive. Utilization of healthcare services by individuals who don't have the Affordable Care Act is likely to show signs of increasing by 2015, posing a "manageable" challenge to health insurers, Borsch wrote. However, the increase in the utilization of these services is likely to be "relatively gradual" compared with similar trends in the past, the analyst contended. Borsch based his forecast on healthcare spending trends during previous economic recoveries. He reduced his 2015 earnings estimate for Aetna to $7 from $7.10 and for United Health to $5.95 from $6. He reduced his 2015 EPS estimates for other companies in the sector, as his earnings outlook for WellPoint (WLP) declined to $9.20 from $9.35, while his estimate for Cigna (CI) for next year dropped to $7.90 from $8. The analyst kept Neutral ratings on both WellPoint and Cigna. Meanwhile, Borsch cut his price target on Aetna to $88 from $91 and on UnitedHealth to $91 from $96. PRICE ACTION: In early afternoon trading, Aetna fell 3% to $76, UnitedHealth slumped 2.5% to $79.50, WellPoint declined 2.5% to $108, and Cigna retreated 2.5% to $89.
10:00 EDTAETOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:08 EDTMPELOn The Fly: Pre-market Movers
Subscribe for More Information
08:58 EDTMPELMelco Crown announces $500M share repurchase program
Subscribe for More Information
08:58 EDTMPELMelco Crown reports Taiwan branch office indicted for alleged banking violations
Subscribe for More Information
08:25 EDTMPELMelco Crown reports Q2 EPS 26c, consensus 36c
Reports Q2 revenue $1.19B, consensus $1.3B.
05:41 EDTAETAetna downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Aetna to Neutral citing less favorable sector trends. The firm lowered its price target for shares to $88 from $91.
August 6, 2014
15:18 EDTMPELMelco Crown technical remarks ahead of earnings
In the prior three months the shares have broadly underperformed the broader averages, falling over 16% including today's drop in price. The move today has put the shares right at the $30 area, which is critical for the longer-view technical health of the shares. While there has been a sharp decline from peak price earlier this year at $45.70, a breakdown below $30 would turn the long-term trend to bearish. If there is negative news, particularly concerning Macau operations where the company is heavily focused, the shares could fall further. Next support below $30 would be at $28,74, $26.53, and $25.53 which is the 52-week low. If the news is better than expected, resistance levels to watch as potential upside objectives would be at $31.97, $35.31, and $36.84. There is a minimal short-base in the name which could exacerbate downside in the event that news is more negative than anticipated.
10:43 EDTRHHBYRoche says Avastin gets EU approval for Ovarian cancer
Roche announced that the European Commission, EU, approved the use of Avastin in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.
06:21 EDTATHNPiper Jaffray to hold a summit
Subscribe for More Information
06:19 EDTRHHBYCFA Society of Minnesota to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use